Risk factor profile and management of cerebrovascular patients in the REACH Registry.

Published

Journal Article

BACKGROUND: Cerebrovascular disease (CVD) is a global public health problem. CVD patients are at high risk of recurrent stroke and other atherothrombotic events. Prevalence of risk factors, comorbidities, utilization of secondary prevention therapies and adherence to guidelines all influence the recurrent event rate. We assessed these factors in 18,992 CVD patients within a worldwide registry of stable outpatients. METHODS: The Reduction of Atherothrombosis for Continued Health Registry recruited >68,000 outpatients (44 countries). The subjects were mainly recruited by general practitioners (44%) and internists (29%) if they had symptomatic CVD, coronary artery disease, peripheral arterial disease (PAD) and/or >or=3 atherothrombotic risk factors. RESULTS: The 18,992 CVD patients suffered a stroke (53.7%), transient ischemic attack (TIA) (27.7%) or both (18.5%); 40% had symptomatic atherothrombotic disease in >or=1 additional vascular beds: 36% coronary artery disease; 10% PAD and 6% both. The prevalence of risk factors at baseline was higher in the TIA subgroup than in the stroke group: treated hypertension (83.5/82.0%; p = 0.02), body mass index >or=30 (26.7/20.8%; p < 0.0001), hypercholesterolemia (65.1/52.1%; p < 0.0001), atrial fibrillation (14.7/11.9%; p < 0.0001) and carotid artery disease (42.3/29.7%; p < 0.0001). CVD patients received antiplatelet agents (81.7%), oral anticoagulants (17.3%), lipid-lowering agents (61.2%) and antihypertensives (87.9%), but guideline treatment targets were frequently not achieved (54.5% had elevated blood pressure at baseline, while 4.5% had untreated diabetes). CONCLUSIONS: A high percentage of CVD patients have additional atherothrombotic disease manifestations. The risk profile puts CVD patients, especially the TIA subgroup, at high risk for future atherothrombotic events. Undertreatment is common worldwide and adherence to guidelines needs to be enforced.

Full Text

Duke Authors

Cited Authors

  • Röther, J; Alberts, MJ; Touzé, E; Mas, J-L; Hill, MD; Michel, P; Bhatt, DL; Aichner, FT; Goto, S; Matsumoto, M; Ohman, EM; Okada, Y; Uchiyama, S; D'Agostino, R; Hirsch, AT; Wilson, PWF; Steg, PG; REACH Registry Investigators,

Published Date

  • 2008

Published In

Volume / Issue

  • 25 / 4

Start / End Page

  • 366 - 374

PubMed ID

  • 18337635

Pubmed Central ID

  • 18337635

Electronic International Standard Serial Number (EISSN)

  • 1421-9786

Digital Object Identifier (DOI)

  • 10.1159/000120687

Language

  • eng

Conference Location

  • Switzerland